ApconiX Toxicology Archives
SOT 58th Annual Meeting & ToxExpo - 1663: Talk by Dr Jane Barber of ApconiX At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, Dr Jane Barber of ApconiX will be giving a talk as part of the Safety Assessment: [...]
ApconiX Exhibiting at SOT Booth Number 2610 ApconiX will be exhibiting on booth number 2610 at the Society of Toxicology 58th Annual Meeting and ToxExpo in Baltimore between 10th and 14th of March. Ruth Roberts, Richard Knight, Michael Morton, Jane Barber, Paul Duffy, Steffen Ernst and Marie Cumberbatch will [...]
Symposium – Dx Toxicology: Strategies for Success in Discovery and Development Attrition due to safety/toxicity remains a challenge in drug discovery and development. Strategies to improve success focus on asking the right questions at the right time around Target, Chemistry and Patient with an emphasis on translation of data [...]
ApconiX Opens a New Office in Sweden ApconiX is excited to announce the opening of our new office in Sweden. The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Gothenburg. ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and [...]
Professor Ruth Roberts Hosts ATS Meeting Professor Ruth Roberts was elected President of the Academy of Toxicology Sciences in June 2018 and holds the position until June 2019. She will be hosting the ATS Annual Business Meeting and Reception at SOT on Tuesday, March 12 where she will be [...]
ApconiX Welcomes Dr Steffen Ernst ApconiX is delighted to welcome Dr Steffen Ernst to our team, as the company begins its international expansion with the formation of its Swedish subsidiary, ApconiX AB. Steffen has worked in preclinical and clinical safety for over 20 years with Hoechst-Schering, Boehringer-Ingelheim, AstraZeneca, Pfizer [...]
ApconiX Welcomes Dr Bjorn Dahl ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development [...]
Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity Abstract Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with [...]
Collaboration and competition: ethics in toxicology What are our attitudes to research resourcing, publication and the peer review system? The British Toxicology Society (BTS) is conducting a survey to establish attitudes of toxicologists to key questions such as ‘I believe collaboration to be important in driving toxicology research in [...]
Choosing the right non-clinical CRO Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical [...]
